Singapore markets close in 6 hours 56 minutes
  • Straits Times Index

    3,217.20
    -0.97 (-0.03%)
     
  • Nikkei

    28,838.15
    -260.09 (-0.89%)
     
  • Hang Seng

    25,623.78
    -4.96 (-0.02%)
     
  • FTSE 100

    7,253.27
    -24.35 (-0.33%)
     
  • BTC-USD

    58,856.45
    -1,698.59 (-2.81%)
     
  • CMC Crypto 200

    1,410.22
    -64.11 (-4.35%)
     
  • S&P 500

    4,551.68
    -23.11 (-0.51%)
     
  • Dow

    35,490.69
    -266.19 (-0.74%)
     
  • Nasdaq

    15,235.84
    +0.12 (+0.00%)
     
  • Gold

    1,800.20
    +1.40 (+0.08%)
     
  • Crude Oil

    81.11
    -1.55 (-1.88%)
     
  • 10-Yr Bond

    1.5290
    -0.0900 (-5.56%)
     
  • FTSE Bursa Malaysia

    1,578.76
    -4.32 (-0.27%)
     
  • Jakarta Composite Index

    6,602.21
    -54.73 (-0.82%)
     
  • PSE Index

    7,201.52
    -28.63 (-0.40%)
     

iBio to Participate in the Cantor 2021 Virtual Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BRYAN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that the Company’s Chairman & CEO, Tom Isett, and its CSO, Martin Brenner, DVM, Ph.D., will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 10:00 a.m. Eastern Time.

The fireside chat will be broadcast live and archived on the Company's website at www.ibioinc.com under "News & Events" in the Investors section.

About iBio, Inc.

iBio is a developer of next-generation biopharmaceuticals and a pioneer in sustainable, plant-based biologics manufacturing. Its FastPharming System® combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is developing proprietary biopharmaceuticals for the treatment of cancers, as well as fibrotic and infectious diseases. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with Glycaneering Development Services™ for advanced recombinant protein design. For more information, visit www.ibioinc.com.

Contact:

Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580
skilmer@ibioinc.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting